To the content
4 . 2022

Use of Subetta® in the treatment of impaired glucose tolerance in a patient with metformin intolerance (clinical case)

Abstract

The aim of the article is to show the possibility of Subetta® using in impaired glucose tolerance treatment based on a clinical case report.

Material and methods. Prescription of Subetta® for the patient with prediabetes has a positive effect on insulin resistance and gave a significant positive result, such as a decrease in body weight and visceral adipose tissue volume. This allowed to improve the sensitivity of peripheral tissues to insulin and resulted to the normalization of glucose and lipid metabolism, improvement of hepatic transaminases, increased testosterone levels of the patient.

Conclusion. Correction of insulin resistance is an important therapeutical component in glucose metabolism disorders’ treatment. An integrated approach is needed to reduce insulin resistance effectively. Subetta® has a good positive effect in combination, and in some cases in monotherapy, as it is shown in the case report.

Keywords:insulin resistance; glucose metabolism disorders; combination and monotherapy; improvement of insulin receptor sensitivity; Subetta®

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Kosareva O.V., Dolgikh Yu.A., Sharonova L.A. Use of Subetta® in the treatment of impaired glucose tolerance in a patient with metformin intolerance (clinical case). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (4): 95–100. DOI: https://doi.org/10.33029/2304-9529-2022-11-4-95-100 (in Russian)

References

1. Drapkina O.M., Shifrina J.O., Ivashkin V.T. Molecular mechanisms of insulin resistance. Arterial’naya gipertenziya [Arterial Hypertension]. 2010; 16 (5): 436–40. (in Russian)]

2. Verbovoy A.F., Mitroshina E.V., Dolgikh Yu.A. Adipokines, insulin resistance and activity of the sympathoadrenal system in obese adolescents who manifest in puberty. Ozhirenie i metabolism [Obesity and Metabolism]. 2012; 9 (2): 49–52. DOI: https://doi.org/10.14341/omet2012249-52 (in Russian)

3. Shagalova N. Ya. Insulin resistance – benefit or harm? Sovremennye problemy nauki i obrazovaniya [Modern Problems of Science and Education]. 2016; (2): 89. (in Russian)

4. Zinker B.A., Rondinone C.M., Trevillyan J.M., Gum R.J., Ciampit J.E. PTP IB antisense oligonucleotide lowers PTPIB protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA. 2002; 99 (17): 11 357–62. DOI: https://doi.org/10.1073/pnas.142298199

5. Samuel V.T., Petersen K.F., Shulman G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet. 2010; 375 (9733): 2267–77. DOI: https://doi.org/10.1016/S0140-6736(10)60408-4

6. URL: https://www.rlsnet.ru/drugs/metformin-1982

7. Chernikova N.A., Gilyarevsky S.R., Dudinskaya E.N. Influence of insulin resistance on development on the development of complications of type 2 diabetes mellitus and ways of correction in old age. III All-Russian Congress on Gerontology and Geriatrics. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15 (25): 30–6. (in Russian)

8. Gorbunov E.A., Nicoll J., Myslivets A.A., et al. Subetta increases the sensitivity of human muscle cells to insulin. Byulleten’ eksperimental’noi biologii i meditsiny [Bulletin of Experimental Biology and Medicine]. 2015; 159 (4): 454–6. DOI: https://doi.org/10.1007/s10517-015-2992-8 (in Russian)

9. Omilaenko N.V., Vorobyev S.V., Nazheva M.I., Demidov I.A. The effectiveness of therapy based on the use of midget dozes of antibodies to C-end fragment beta-subunit of the receptor for insulin and antibodies to endothelial NO- synthase in patients with non-alcoholic fatty liver disease with mellitus diabetes type 2. Fundamentalnye issledovaniya [Basic Research]. 2015; (1): 1888–92. (in Russian)

10. Mkrtumyan A.M., Vorob’ev S.V., Volkova A.R., Vorokhobina N.V. Effect of Subetta on glycemic control in patients with type 2 diabetes mellitus: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial. Farmateka [Pharmateca]. 2020; 27 (12): 38–48. (in Russian)

11. Mkrtumyan A.M., Egshatyan L.V. Subetta is a novel insulin receptor activator. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2019; 15 (12): 12–7. (in Russian)

12. Mkrtumyan A.M. VITA observational program: evaluation of the efficacy and safety of Subetta in the complex therapy of type 2 diabetes mellitus in outpatients. Effektivnaya farmakoterapiya [Effective Pharmacotherapy]. 2020; 16 (2): 12–7. (in Russian)

13. Rogova N.V., Ryazanova A. Yu. Correction of the metabolic profile of obese patients with type 2 diabetes mellitus with an antidiabetic drug with an active ingredient based on antibodies to the C-terminal fragment of the β-subunit of the insulin receptor. Lechashchiy vrach [Attending Physician]. 2019; (8): 72–8. (in Russian)

14. Balukova E.V., Baryshnikova N.V., Belousova L.N. Nonalcoholic fatty liver disease: current state of problem. Farmateka [Pharmateca]. 2016; (2): 63–8. (in Russian)

15. Agarwal P.K., Singh P., Chowdhury S., Sharma S.K., Majumdar A., Shah P., et al. A study to evaluate the prevalence of hypogonadism in Indian males with type-2 diabetes mellitus. Indian J Endocrinol Metab. 2017; 21: 64–70. DOI: https://doi.org/10.4103/2230-8210.196008

16. Instruction for medical use of Subetta. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9d51d4fe-bc47-4412-a58b-f08095907376&t= (date of access April 17, 2020)

17. Mkrtumyan A., Ametov A., Demidova T., Volkova A., Dudinskaya E., Vertkin A., et al. A new approach to overcome insulin resistance in patients with impaired glucose tolerance: the results of a multicenter, double-blind, placebo-controlled, randomized clinical trial of efficacy and safety of Subetta. J Clin Med. 2022; 11 (5): 1390. DOI: https://doi.org/10.3390/jcm11051390

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
CHIEF EDITOR
Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)
Вскрытие

Journals of «GEOTAR-Media»